Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'

Summary, in English

The AIRE gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with AIRE-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with AIRE-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.

• Author: Nils Landegren; Lindsey B. Rosen; Eva Freyhult; Daniel Eriksson; Tove Fall; Gustav Smith; Elise M.N. Ferre; Petter Brodin; Donald Sharon; Michael Snyder; Michail Lionakis; Mark Anderson; Olle Kämpe
• Department/s: Heart Failure and Mechanical Support; Cardiovascular Epigenetics; EpiHealth: Epidemiology for Health; EXODIAB: Excellence of Diabetes Research in Sweden; Molecular Epidemiology and Cardiology; WCMM-Wallenberg Centre for Molecular Medicine
• Publishing year: 2019-06-27
• Language: English
• Publication/Series: eLife
• Volume: 8
• Links: http://dx.doi.org/10.7554/eLife.43578
• Document type: Journal article
• Publisher: eLife Sciences Publications
• Topic: Endocrinology and Diabetes; Immunology in the medical area
• Keywords: APS1/APECED; autoantibody; autoantigen; human; human biology; immune tolerance; immunology; inflammation; medicine; type 1 diabetes
• Status: Published
• Research group: Heart Failure and Mechanical Support; Cardiovascular Epigenetics; Molecular Epidemiology and Cardiology
• ISBN/ISSN/Other: ISSN: 2050-084X